Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'GALANTAMINE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 37 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Aerssens, J; Raeymaekers, P; Lilienfeld, S; Geerts, H; Konings, F; Parys, W
      APOE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease

      DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
    2. Small, G
      Meeting the challenges of vascular dementia - Introduction

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    3. Maelicke, A
      The pharmacological rationale for treating vascular dementia with galantamine (Reminyl(Tau Mu))

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    4. Pearson, VE
      Galantamine: A new Alzheimer drug with a past life

      ANNALS OF PHARMACOTHERAPY
    5. O'Brien, JT; Ballard, CG
      Drugs for Alzheimer's disease - Cholinesterase inhibitors have passed NICE's hurdle

      BRITISH MEDICAL JOURNAL
    6. Bullock, R
      Drug treatment in dementia

      CURRENT OPINION IN PSYCHIATRY
    7. Mega, MS; Cummings, JL; O'Connor, SM; Dinov, ID; Reback, E; Felix, J; Masterman, DL; Phelps, MF; Small, GW; Toga, AW
      Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease

      NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY
    8. DeKosky, ST; Ferris, SH
      Cornerstones in the management of Alzheimer's disease - CME accredited symposium at World Alzheimer Congress (WAC) 2000 Meeting - 9-18 July 2000 - Washington DC, USA - Introduction

      ALZHEIMER DISEASE & ASSOCIATED DISORDERS
    9. Albuquerque, EX; Santos, MD; Alkondon, M; Pereira, EFR; Maelicke, A
      Modulation of nicotinic receptor activity in the central nervous system: Anovel approach to the treatment of Alzheimer disease

      ALZHEIMER DISEASE & ASSOCIATED DISORDERS
    10. Tariot, PN
      Maintaining cognitive function in Alzheimer disease: How effective are current treatments?

      ALZHEIMER DISEASE & ASSOCIATED DISORDERS
    11. Winblad, B
      Maintaining functional and behavioral abilities in Alzheimer disease

      ALZHEIMER DISEASE & ASSOCIATED DISORDERS
    12. Wilkinson, D; Murray, J
      Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

      INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
    13. Rivas-Vazquez, RA
      Cholinesterase inhibitors: Current pharmacological treatments for Alzheimer's disease

      PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
    14. Frisoni, GB
      Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice

      JOURNAL OF NEUROLOGY
    15. Patterson, C; Gauthier, S
      Canadian consensus conference on dementia: Two years later

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    16. Rainer, M; Mucke, HAM; Kruger-Rainer, C; Kraxberger, E; Haushofer, M; Jellinger, KA
      Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics

      JOURNAL OF NEURAL TRANSMISSION
    17. Ferris, SH
      Switching previous therapies for Alzheimer's disease to galantamine

      CLINICAL THERAPEUTICS
    18. Maelicke, A
      Pharmacokinetic rationale for switching from donepezil to galantamine

      CLINICAL THERAPEUTICS
    19. Farlow, MR
      Pharmacokinetic profiles of current therapies for Alzheimer's disease: Implications for switching to galantamine

      CLINICAL THERAPEUTICS
    20. Rasmusen, L; Yan, B; Robillard, A; Dunbar, F
      Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: Ongoing clinical trials

      CLINICAL THERAPEUTICS
    21. Keltner, NL; Zielinski, AL; Hardin, MS
      Drugs used for cognitive symptoms of Alzheimer's disease

      PERSPECTIVES IN PSYCHIATRIC CARE
    22. Feldman, H; Gauthier, S; Hecker, J; Vellas, B; Subbiah, P; Whalen, E
      A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

      NEUROLOGY
    23. Mohs, RC; Doody, RS; Morris, JC; Ieni, JR; Rogers, SL; Perdomo, CA; Pratt, RD
      A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

      NEUROLOGY
    24. Winblad, B; Engedal, K; Soininen, H; Verhey, F; Waldemar, G; Wimo, A; Wetterholm, AL; Zhang, R; Haglund, A; Subbiah, P
      A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD

      NEUROLOGY
    25. Rockwood, K; Mintzer, J; Truyen, L; Wessel, T; Wilkinson, D
      Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    26. Maelicke, A; Samochocki, M; Jostock, R; Fehrenbacher, A; Ludwig, J; Albuquerque, EX; Zerlin, M
      Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

      BIOLOGICAL PSYCHIATRY
    27. Coyle, J; Kershaw, P
      Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease

      BIOLOGICAL PSYCHIATRY
    28. Winblad, B; Wimo, A; Almkvist, O
      Outcome measures in Alzheimer's disease: Do they go far enough?

      DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
    29. Maelicke, A
      Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease

      DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
    30. Lilienfeld, S; Parys, W
      Galantamine: Additional benefits to patients with Alzheimer's disease

      DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
    31. Blesa, R
      Galantamine: Therapeutic effects beyond cognition

      DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
    32. Sramek, JJ; Frackiewicz, EJ; Cutler, NR
      Review of the acetylcholinesterase inhibitor galanthamine

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    33. Woodruff-Pak, DS; Santos, IS
      Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease

      BEHAVIOURAL BRAIN RESEARCH
    34. Raskind, MA; Peskind, ER; Wessel, T; Yuan, W
      Galantamine in AD - A 6-month randomized, placebo-controlled trial with a 6-month extension

      NEUROLOGY
    35. Tariot, PN; Solomon, PR; Morris, JC; Kershaw, P; Lilienfeld, S; Ding, C
      A 5-month, randomized, placebo-controlled trial of galantamine in AD

      NEUROLOGY
    36. Scott, LJ; Goa, KL
      Galantamine - A review of its use in Alzheimer's disease

      DRUGS
    37. Samochocki, M; Zerlin, M; Jostock, R; Kormelink, PJG; Luyten, WHM; Albuquerque, EX; Maelicke, A
      Galantamine is an allosterically potentiating ligand of the human alpha 4/beta 2 nAChR

      ACTA NEUROLOGICA SCANDINAVICA


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/02/20 alle ore 09:18:36